Crystalline form of triethylenetetramine tetrahydrochloride and its pharmaceutical use
US10947184B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2020 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Jun 30, 2040 |
Classification
- Technology area (CPC —)General
Abstract
The present invention describes a new crystalline form of triethylenetetramine tetrachloride which has improved room temperature stability over known forms and over the dichloride salt. The new crystalline form is characterised by having peaks in an XRPD spectrum at 22.9, 25.4, 25.8, 26.6, 34.6 and 35.3±0.1°2θ and Raman shifts 943, 1173, 1527 and 1612±5 cm−1. The crystalline form of triethylenetetramine tetrachloride is useful in the treatment of Wilson's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.